On November 21, 2019 BostonGene Corporation (BostonGene), a Boston-based biomedical software company, reported that as a result of its collaborations, multiple abstracts have been accepted for presentation at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida (Press release, BostonGene, NOV 21, 2019, View Source [SID1234551593]). In addition, BostonGene will exhibit at booth #152 in Hall B.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations will provide results demonstrating the role of the tumor microenvironment in cancer classification and treatment outcomes. By combing whole exome and transcriptome sequencing analysis, the significance of stromal and immune compartments of microenvironment in therapeutically relevant categories of Mantle Cell Lymphomas and Diffuse Large B-Cell Lymphoma (DLBCL) is identified.
POSTER PRESENTATION
Sunday, December 8, 2019: 6:00 PM – 8:00 PM in Hall B, Level 2
Title: Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma (Abstract 2762)
Presenter: Krystle Nomie, The University of Texas MD Anderson Cancer Center
Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster II
ORAL PRESENTATION
Monday, December 9, 2019: 10:45 AM in Tangerine 2 (WF2), Level 2
Title: Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling (Abstract 656)
Presenter: Leandro Cerchietti, MD, Weill Cornell Medicine
Session: 622. Lymphoma Biology—Non-Genetic Studies: Tumor Microenvironment
Additional information on abstracts for the ASH (Free ASH Whitepaper) Annual Meeting can be found here: View Source
"We are excited to share our success as a strategic collaborator with two of the leading cancer centers in the world at this year’s ASH (Free ASH Whitepaper) event. We look forward to showcasing our innovative platform that will ultimately impact and improve cancer patients’ chances for survival," said Andrew Feinberg, President & CEO at BostonGene.